155 related articles for article (PubMed ID: 25558303)
21. Higher Predictive Value Positive for MMA Than ACA MTM Eligibility Criteria Among Racial and Ethnic Minorities: An Observational Study.
Qiao Y; Spivey CA; Wang J; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns MA
Inquiry; 2018; 55():46958018795749. PubMed ID: 30175638
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Medication Review Completion Rates and Disparities After Medicare Star Rating Measure.
Hung A; Wilson L; Smith VA; Pavon JM; Sloan CE; Hastings SN; Farley J; Maciejewski ML
JAMA Health Forum; 2024 May; 5(5):e240807. PubMed ID: 38700854
[TBL] [Abstract][Full Text] [Related]
23. Trends in Medicare Part D Medication Therapy Management Eligibility Criteria.
Wang J; Shih YC; Qin Y; Young T; Thomas Z; Spivey CA; Solomon DK; Chisholm-Burns M
Am Health Drug Benefits; 2015; 8(5):247-55. PubMed ID: 26380030
[TBL] [Abstract][Full Text] [Related]
24. Solving racial/ethnic disparities associated with Medicare Part D Star Ratings.
Dong X; Tsang CCS; Browning JA; Sim Y; Wan JY; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Wang J
Curr Med Res Opin; 2023 Jul; 39(7):963-971. PubMed ID: 37219396
[TBL] [Abstract][Full Text] [Related]
25. Evolution of the Medicare Part D Medication Therapy Management Program from Inception in 2006 to the Present.
Gray C; Cooke CE; Brandt N
Am Health Drug Benefits; 2019 Sep; 12(5):243-251. PubMed ID: 32015791
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of Medication Therapy Management Program Across Racial and Ethnic Groups Among Medicare Beneficiaries.
Tsang CCS; Shih YT; Dong X; Garuccio J; Browning JA; Wan JY; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Zeng R; Wang J
Value Health; 2023 May; 26(5):649-657. PubMed ID: 36376143
[TBL] [Abstract][Full Text] [Related]
27. Racial and ethnic disparities related to the Medicare Part D Medication Therapy Management Program.
Allen A; Hung A
J Manag Care Spec Pharm; 2024 Jun; 30(6):609-616. PubMed ID: 38824629
[TBL] [Abstract][Full Text] [Related]
28. Should eligibility for medication therapy management be based on drug adherence?
Stuart B; Loh E; Miller L; Roberto P
J Manag Care Pharm; 2014 Jan; 20(1):66-75. PubMed ID: 24511767
[TBL] [Abstract][Full Text] [Related]
29. Effects of Medicare Part D medication therapy management on racial/ethnic disparities in adherence to antidementia medications among patients with Alzheimer's disease and related dementias: An observational study.
Dong X; Tsang CCS; Wan JY; Chisholm-Burns MA; Finch CK; Tsao JW; Browning JA; Garuccio J; Zeng R; Wang J
Explor Res Clin Soc Pharm; 2024 Mar; 13():100420. PubMed ID: 38420610
[TBL] [Abstract][Full Text] [Related]
30. Assessing Medicare Beneficiary Eligibility for Medication Therapy Management Programs Using PINNACLE, a National Cardiovascular Data Registry.
Spinler SA; Cziraky MJ; Tang F; Dueñas GG; Thomas T; Reinhold JA; Willey VJ
Am Health Drug Benefits; 2013 Sep; 6(7):367-74. PubMed ID: 24991369
[TBL] [Abstract][Full Text] [Related]
31. Medication Therapy Management Delivery by Community Pharmacists: Insights from a National Sample of Medicare Part D Beneficiaries.
Adeoye OA; Farley JF; Coe AB; Pestka DL; Farris KB; Zillich AJ; Snyder ME
J Am Coll Clin Pharm; 2019 Aug; 2(4):373-382. PubMed ID: 31460497
[TBL] [Abstract][Full Text] [Related]
32. Effect of Cost-Related Medication Non-adherence Among Older Adults With Medication Therapy Management.
Zhang W; Lv G; Xiong X; Li M
Front Med (Lausanne); 2021; 8():670034. PubMed ID: 34222282
[No Abstract] [Full Text] [Related]
33. Effects of star ratings bonus payments on disparities in medication utilization issues.
Tsang CCS; Garuccio J; Dong X; Sim Y; Wang J
Explor Res Clin Soc Pharm; 2023 Sep; 11():100323. PubMed ID: 37694164
[TBL] [Abstract][Full Text] [Related]
34. Racial and ethnic disparities associated with the measure for drug-drug interactions among Medicare beneficiaries.
Browning J; Tsang CCS; Wan JY; Chisholm-Burns MA; Dagogo-Jack S; Cushman WC; Dong X; Wang J
J Am Pharm Assoc (2003); 2022; 62(1):142-149. PubMed ID: 34509379
[TBL] [Abstract][Full Text] [Related]
35. Patterns and predictors of older adult Medicare Part D beneficiaries' receipt of medication therapy management.
Coe AB; Adeoye-Olatunde OA; Pestka DL; Snyder ME; Zillich AJ; Farris KB; Farley JF
Res Social Adm Pharm; 2020 Sep; 16(9):1208-1214. PubMed ID: 31859225
[TBL] [Abstract][Full Text] [Related]
36. Effects of Part D Star Ratings on racial and ethnic disparities in health care costs.
Tsang CCS; Sim Y; Christensen ML; Wang J
Explor Res Clin Soc Pharm; 2023 Mar; 9():100250. PubMed ID: 37091627
[TBL] [Abstract][Full Text] [Related]
37. Predictive Value Positive of MTM Eligibility Criteria under MMA and ACA in Identifying Individuals with Medication Utilization Issues.
Qiao Y; Spivey CA; Wang J; Shih YT; Wan JY; Kuhle J; Dagogo-Jack S; Cushman WC; Chisholm-Burns M
J Pharm Health Serv Res; 2018 Dec; 9(4):393-401. PubMed ID: 30906425
[TBL] [Abstract][Full Text] [Related]
38. Racial/ethnic disparities in measure calculations for Part D Star Ratings among Medicare beneficiaries with diabetes, hypertension, and/or hyperlipidemia.
Steve Tsang CC; Wan JY; Chisholm-Burns MA; Li M; Dagogo-Jack S; Cushman WC; Hines LE; Wang J
Res Social Adm Pharm; 2021 Aug; 17(8):1469-1477. PubMed ID: 33272859
[TBL] [Abstract][Full Text] [Related]
39. A medication therapy management program's impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes.
Fox D; Ried LD; Klein GE; Myers W; Foli K
J Am Pharm Assoc (2003); 2009; 49(2):192-9. PubMed ID: 19289345
[TBL] [Abstract][Full Text] [Related]
40. The effects of medication therapy management on medication utilization among Medicare beneficiaries with HIV/AIDS.
Zhang X; Wang J
J Am Pharm Assoc (2003); 2024; 64(2):463-470.e2. PubMed ID: 38182001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
